Breath Diagnostic Technologies
Scentech Medical is a company specializing in Breath Test Diagnostics. It has been established on the infrastructure of several successful experiments over the last decade, including clinical trials, for the detection of infectious diseases, cancers, and other illnesses by a straightforward test of the patient's breath sample.
Mapping the Coronavirus Fingerprint
Scentech Medical has joined forces with the medical staff of Meir Medical Center in Kfar Saba to conduct a trial aiming to map the Coronavirus fingerprint. During the trial, breath samples of patients with various stages of the disease will be collected and analyzed to identify the unique characteristics of the gases emitted by the Coronavirus.
Samples for the study will be collected using Owlstone Medical's Breath Biopsy®️ platform, which includes the ReCIVA®️ Breath Sampler and CASPER®️ Portable Air Supply. For more information, visit
Real-Time Accurate Disease Identification Breath Analysis
Our technology provides a solution for highly accurate breath analysis in real-time and at the Point of Care. Identifying infectious diseases in their early stages can be critical in preventing the spread of an epidemic like the Coronavirus.
Every living organism has unique metabolic processes that produce a particular signature. With the company’s exclusive technology and methodology for identifying "Volatile Organic Compounds" (VOCs) in exhaled breath, we can identify the direct compounds associated with the virus’s activity.
Scentech Medical’s laboratory, located in the Weizmann Science Park, Ness Ziona, Israel,
is uniquely suited for mapping biomarkers in exhaled breath thanks to its state-of-the-art equipment and a team of highly skilled researchers.
RBT - Rapid Breath Test
Developing a Breath Test for Coronavirus Detection In the last few months,
in light of the coronavirus crisis, Scentech-Medical opened a new division which focuses on the development of a breath test for the detection of coronavirus (SARS-Cov-2) in human breath:
The development is based on the detection and mapping of biomarkers, in the form of VOCs, which are associated with the virus’s activity in the body and are found in the breath of symptomatic and asymptomatic patients. The breath test is expected to offer many advantages over existing technologies, including:
* Detection of asymptomatic patients
* Rapid test with on-the-spot results
* Better accuracy Lower operational costs per test
* Does not require the use of reagents or a trained personnel to administer the test
* Since the test recognizes biomarkers associated with the virus, it can be updated/adapted relatively easily to new mutations or viruses.
* All Pictures shown are for illustration purpose only
Chief Executive Officer
Dr. Rom Eliaz
Executive board member
Dr. Udi Cantor
Chief Medical Officer
Chief Research Officer
Yaniv combines extensive financial expertise with significant experience in accelerating company growth. He was the Chief Strategy Officer at Excellence Investment House, where he managed over 35 billion dollars in assets. Yaniv is an NFX Alumnus and has an MA in Economics from Tel Aviv University.
Dr. Eliaz is Founder and Managing Director at Elrom Ventures. Rom was Managing Director and aMoon Fund, the Head of Merck ventures’ Fund and Bio-Incubator in Israel ,VP of Innovative Branded Products at Teva and CEO of NasVax (TASE: NSVX) and Immcure Therapeutics, VP of Product Development at, Intradigm (acquired by Silence Therapeutics), Rinat Neuroscience (acquired by Pfizer) and Alza (acquired by J&J).Rom received his PhD (cum-laude) chemical engineering and Biotechnology from the Weizmann Institute and Ben-Gurion University (BGU) and MBA from Harvard and Boston University joint program at BGU.
Specialist in General and Urological Surgery In the past, he managed the organ transplant unit at Sheba Medical Center. He is a graduate of the FDA standard GMP examiners and was certified in Health Systems Management, at the Heller School, University of Brandeis, Boston, USA.
Additionally, Dr. Cantor has served as the Head of Quality and Technology Administration in the USSR and as Head of the Technion Risk Management Training Village in Haifa.
He founded and has served as the Head of the Medical Policy Division of the Medical Association in Israel.
Drew is a seasoned expert in the areas of metabolomics, breath analysis, and genetic expression diagnostics. He served on multiple advisory panels addressing the planning for pandemics and global health threats. He continues to be an outspoken advocate for the need for rapid diagnostic tools based on genetic expression, as a means to contain the spread of infectious diseases and improve health outcomes.
Dr. Keren-Or Amar
Dr. Regina Sinelnikov
Healthcare Business Consultant
Analytical Lab Manager
Dr. Amar earned her Ph.D. at the Faculty of Life Science, Bar-Ilan University, and completed post-doctoral studies at the Lautenberg Center for Immunology and Cancer Research at the Faculty of Medicine, Hebrew University, Jerusalem. Further, she holds a BSc and MSc from the Faculty of Biology at the Technion Israel Institute of Technology, as well as an MA in Law from Bar-Ilan University.
Since graduating, she has held a number of management positions in the Biomed and Pharma Industries. Currently she serves as VP Business Development at Yissum, of the Hebrew University. She served as the manager of ShizimXL medical devices accelerator and established and managed the research and development authority at Shaare Zedek Medical Center.
Regina brings her drive and passion for meaningful science to her role as the Analytical Laboratory Manager. She holds a PhD in Materials Chemistry from the University of Alberta and a BSc in Chemistry and Computer Science from Western University. Regina honed her analytical skills as a researcher at the Analytical Laboratory of the Israeli Air Force, where she specialized in the identification and method development for the analysis of non-metal materials used in the aviation industry.
Analytical Research Chemist
Konstantin has over twenty years of analytical experience as the head of the Analytical Laboratory in the Israeli Air Force. Konstantin’s expert command of numerous analytical tools served him well in aircraft failure investigations, air quality analyses, and applied research at the IAF. He developed multiple methods for the quality assurance, predictive maintenance, and forensic analysis of non-metal materials. The state-of-the-art laboratory under his command held unique capabilities, some of which were developed in-house. Konstantin obtained his BSc in Chemistry and MSc in Medical Science from Tel-Aviv University.
Dr. Natalie Dror
VP Clinical & Regulatory Affairs
Dr. Natalie has extensive leadership experience in medical device product management including R&D, pre-clinical studies, clinical studies design, the establishment of regulatory strategies, and submissions to regulatory authorities worldwide. Natalie received her MSc in Medicine, and her PhD in Biotechnology from the Technion - Israel Institute of Technology.
Dr. Diklah Geva
Head of Data Science
Dr. Geva brings over 20 years of data analysis leading to successful developments of classification algorithms for a variety of biomedical applications as well as clinical trials repots submission to the FDA. Diklah holds a PhD in Epidemiology and Public health from Ben Gurion University, a MSc. in Biostatistics from university of Pittsburgh and a BA in Statistics from the university of Haifa along with additional MBA in Entrepreneurship & Innovation from the Israeli branch at Ramat Aviv of Swinburn University. Diklah servs as the principal biostatistician of various clinical trials initiated by Israeli and international companies. In addition, she functions as a consultant to the Ministry of health Institute of Quality and Standard of Medical Product, s for over 15 years. Diklah is a great fan of R and is brilliant in data visualizations.